← United States · Coverage record
US · SEC FORM 4
Akebia Therapeutics, Inc.
AKBA · Nasdaq · CIK 0001517022 · Healthcare · Drug Manufacturers—Specialty & Generic
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
8 Form 4 transaction lines observed in the same window
1 sales · 7 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-04 · Butler John P..
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -12.7%
- 3M
- -34.2%
- 6M
- -38.0%
- 12M
- —
Volatility & liquidity
- Volatility
- 78.2%
- Beta
- —
- Avg daily value
- —
Valuation
- Market cap
- —
- P/E
- —
Fundamentals
- Profit margin
- -2.2%
- ROE
- -16.3%
- Industry
- Drug Manufacturers—Specialty & Generic
Market data
Price data up to: 2026-10-02 · Price source: OpenBB/yfinance · From SEC filings: Profit margin, ROE · Fiscal year ended: 2025-12-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 22,481,147
- Previous report
- 20,504,915
- Avg daily volume
- 6,412,381
- Days to cover
- 3.5
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Butler John P. | Purchase (P) | Common Stock | 69,270 | USD 1.25 | USD 86,588 | SEC filing ↗ |
Form 4 evidence
31 transaction lines in the latest 365-day window; 219 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. | Option exercise / conversion (M) | Common Stock | 350,000 | USD 0.63 | USD 220,500 | SEC filing ↗ |
| 2026-06-29 | Ostrowski Erik | Sale (S) | Common Stock | 56,019 | USD 1.11 | USD 62,181 | SEC filing ↗ |
| 2026-06-17 | ZUMWALT LEANNE M | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (22 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. | Option exercise / conversion (M) | Common Stock | 350,000 | USD 0.63 | USD 220,500 | SEC filing ↗ |
| 2026-06-29 | Ostrowski Erik | Sale (S) | Common Stock | 56,019 | USD 1.11 | USD 62,181 | SEC filing ↗ |
| 2026-06-17 | ZUMWALT LEANNE M | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | Wolf Myles | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | Smith Cynthia | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | ROGERS MICHAEL W | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | FRIESON RON | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-06-17 | ADAMS ADRIAN | Award / grant (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-04 | Butler John P. | Purchase (P) | Common Stock | 69,270 | USD 1.25 | USD 86,588 | SEC filing ↗ |
| 2026-02-02 | Rucci Carolyn M. | Sale (S) | Common Stock | 69,772 | USD 1.39 | USD 96,983 | SEC filing ↗ |
| 2026-02-02 | Ostrowski Erik | Sale (S) | Common Stock | 34,951 | USD 1.39 | USD 48,582 | SEC filing ↗ |
| 2026-02-02 | Malabre Richard C | Sale (S) | Common Stock | 49,524 | USD 1.39 | USD 68,838 | SEC filing ↗ |
| 2026-02-02 | Grund Nicholas | Sale (S) | Common Stock | 84,829 | USD 1.39 | USD 117,912 | SEC filing ↗ |
| 2026-02-02 | Butler John P. | Sale (S) | Common Stock | 341,305 | USD 1.39 | USD 474,414 | SEC filing ↗ |
| 2026-02-02 | Butler John P. | Award / grant (A) | Common Stock | 175,250 | USD 1.41 | USD 247,102 | SEC filing ↗ |
| 2026-02-02 | Burke Steven Keith | Sale (S) | Common Stock | 67,658 | USD 1.39 | USD 94,045 | SEC filing ↗ |
| 2026-01-30 | Rucci Carolyn M. | Award / grant (A) | Common Stock | 190,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-30 | Ostrowski Erik | Award / grant (A) | Common Stock | 204,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-30 | Malabre Richard C | Award / grant (A) | Common Stock | 79,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-30 | Grund Nicholas | Award / grant (A) | Common Stock | 204,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-30 | Butler John P. | Award / grant (A) | Common Stock | 743,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-30 | Burke Steven Keith | Award / grant (A) | Common Stock | 204,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | AKBA |
| CIK | 0001517022 |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 219 transaction lines from 2020-02-28 to 2026-08-06 1 P purchase lines · 110 S sale lines · 108 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.